SRSF5 Antibody

What is SRSF5 and what biological functions does it perform?

SRSF5 is a serine and arginine rich splicing factor belonging to the SR protein family. Also known as HRS, SRP40, and SFRS5, this 31.3 kilodalton nuclear protein plays essential roles in both constitutive and alternative pre-mRNA splicing . SRSF5 contains RNA recognition motifs (RRMs) that enable direct binding to specific RNA sequences, with the RRM2 domain being particularly important for RNA interactions . As a splicing regulator, SRSF5 modulates which exons are included or excluded during mRNA processing, thereby influencing gene expression patterns and protein diversity.

The functional importance of SRSF5 extends beyond normal cellular processes. It has been implicated in viral pathogenesis, particularly influenza A virus infection, where it facilitates viral replication by promoting alternative splicing of viral transcripts . Recent studies have also identified SRSF5 as a potential tumor suppressor in ER-positive breast cancer, where its downregulation is associated with tamoxifen resistance and poor prognosis . This multifaceted role in both normal cellular processes and disease states makes SRSF5 an important research target.

What applications are validated for SRSF5 antibodies in research?

SRSF5 antibodies have been validated for various experimental applications, enabling comprehensive investigation of this splicing factor. According to available product information, these applications include:

• Western Blot (WB): For detecting and quantifying SRSF5 protein expression in cell or tissue lysates

• Immunocytochemistry (ICC)/Immunofluorescence (IF): For visualizing subcellular localization of SRSF5, particularly its nuclear distribution where splicing occurs

• Immunohistochemistry (IHC): For examining SRSF5 expression patterns in tissue sections, including paraffin-embedded specimens (IHC-p)

• ELISA: For quantitative measurement of SRSF5 protein levels

• Flow Cytometry (FCM): For analyzing SRSF5 expression at the single-cell level

Beyond these standard applications, research articles demonstrate the successful use of SRSF5 antibodies in specialized techniques including RNA immunoprecipitation (RIP) . In these studies, SRSF5 antibodies effectively immunoprecipitated SRSF5-RNA complexes, showing approximately 10-fold enrichment of bound viral M mRNA compared to control β-actin mRNA . This technique has proven invaluable for identifying RNA targets of SRSF5 and understanding its regulatory mechanisms in RNA processing.

What species reactivity is available for SRSF5 antibodies?

When selecting an SRSF5 antibody, species reactivity is a critical consideration to ensure compatibility with your experimental model. Current commercial SRSF5 antibodies demonstrate reactivity across several mammalian species:

• Human (Hu): Most SRSF5 antibodies are validated for human samples

• Mouse (Ms): Many antibodies show cross-reactivity with mouse SRSF5

• Rat (Rt): Several antibodies recognize rat SRSF5 protein

Some antibodies are species-specific (human-only), while others exhibit broader cross-reactivity across multiple species. This variation stems from differences in the epitopes targeted and the degree of conservation in these regions across species. Based on gene homology, orthologous SRSF5 proteins exist in canine, porcine, and non-human primate species , suggesting that some antibodies might cross-react with these species, though specific validation would be necessary before use in these models.

When selecting an SRSF5 antibody for your research, carefully evaluate the manufacturer's validation data for your species of interest and consider performing your own validation if using the antibody in a species not explicitly listed in the product specifications.

What are the optimal storage and handling conditions for maintaining SRSF5 antibody activity?

Proper storage and handling of SRSF5 antibodies are essential for maintaining their specificity and sensitivity. According to product information, recommended conditions include:

• Storage buffer: PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3

• Storage temperature: -20°C for long-term preservation

• Critical precaution: Avoid repeated freeze/thaw cycles that can denature antibodies and compromise performance

To maintain antibody integrity over extended periods, consider these additional handling practices:

• Upon receiving a new antibody, aliquot into smaller volumes based on typical experimental usage to minimize freeze/thaw cycles

• Always keep antibodies on ice when in use and return to proper storage promptly

• Use sterile technique when handling antibody solutions to prevent microbial contamination

• Check manufacturer specifications for any product-specific recommendations, as storage conditions may vary between different antibody formulations

• Document lot numbers and maintain records of antibody performance to monitor potential degradation over time

Most SRSF5 antibodies are provided in liquid formulation, which helps maintain stability during storage. Following these guidelines will help ensure consistent antibody performance across experiments and maximize the usable lifetime of your SRSF5 antibodies.

What is the expression pattern of SRSF5 in normal and pathological conditions?

SRSF5 expression patterns vary across tissues and disease states, providing important contextual information for research interpretation:

In normal conditions, SRSF5 predominantly localizes to the nucleus, consistent with its function in pre-mRNA splicing. Immunofluorescence studies typically show nuclear staining patterns, often with a speckled appearance characteristic of splicing factors that concentrate in nuclear speckles (splicing factor compartments).

During viral infections, SRSF5 expression is significantly upregulated. Studies with influenza A virus (IAV) demonstrated that infection induces approximately 3-fold increase in SRSF5 expression in infected mouse lung tissues at 3 days post-infection . This upregulation occurs consistently across different IAV strains, including PR8, H9N2, and H5N1 viruses . The virus-induced expression suggests SRSF5 plays an important role in the cellular response to infection, potentially being exploited by the virus to facilitate its replication.

In cancer research, SRSF5 expression levels correlate with clinical outcomes in certain malignancies. Specifically in ER-positive breast cancer, low SRSF5 expression associates with tamoxifen resistance, local recurrence, and metastasis . Survival analyses revealed that patients with low SRSF5 expression have poorer prognosis, suggesting its potential utility as a prognostic biomarker in this disease context .

These expression patterns highlight SRSF5's dynamic regulation in different physiological and pathological conditions, reinforcing its importance as a research target.

How does SRSF5 regulate alternative splicing during viral infections?

SRSF5 plays a critical role during influenza A virus (IAV) infection through its regulation of viral mRNA splicing. Research has elucidated the detailed molecular mechanism by which SRSF5 promotes viral replication:

SRSF5 specifically regulates the alternative splicing of the viral M gene, which produces two essential viral proteins: M1 (matrix protein) and M2 (ion channel protein). Both proteins are crucial for viral assembly and infectivity. The splicing mechanism involves several key steps:

• Direct RNA binding: SRSF5, through its RNA Recognition Motif 2 (RRM2) domain, directly binds to the M pre-mRNA at three conserved sites (positions 163, 709, and 712) . This specificity was demonstrated through a series of RNA immunoprecipitation experiments showing 10-fold enrichment of M mRNA with SRSF5 antibody .

• U1 snRNP recruitment: Following binding, SRSF5 recruits U1 small nuclear ribonucleoprotein (snRNP) to the M pre-mRNA through interaction with the U1A protein . This recruitment is a critical step in spliceosome assembly and activation.

• Enhanced M2 production: This orchestrated splicing activity increases the production of the M2 protein, which forms an ion channel essential for viral uncoating and release .

Multiple experimental approaches have validated this mechanism:

• Pull-down assays with biotinylated M mRNA demonstrated specific SRSF5 binding

• RNA fluorescence in situ hybridization showed increasing nuclear colocalization of SRSF5 with M mRNA during infection progression

• Mutational studies revealed that altering the three SRSF5 binding sites significantly attenuated virus replication and pathogenesis in vivo

The functional significance of this mechanism is highlighted by the observation that SRSF5 conditional knockout in mouse lung tissue protected against lethal IAV challenge . This protective effect makes SRSF5 a potential host-derived antiviral target.

What is SRSF5's role in cancer biology and therapeutic resistance?

SRSF5 has emerged as an important regulator of therapeutic response in cancer, particularly in the context of endocrine therapy resistance in breast cancer. Recent research has revealed a mechanistic understanding of how SRSF5 influences treatment outcomes:

In ER-positive breast cancer, SRSF5 regulates the alternative splicing of the Nuclear Receptor Corepressor 2 (NCOR2) gene, specifically controlling the inclusion/exclusion of exon 11 . When SRSF5 levels are reduced, exon 11 is more frequently excluded from the mature mRNA, leading to the production of a variant called BQ323636.1 (BQ) . Overexpression of this BQ variant confers resistance to tamoxifen, a widely used selective estrogen receptor modulator for treating ER-positive breast cancer .

The clinical relevance of this mechanism is supported by several findings:

These findings suggest that SRSF5 functions as a tumor suppressor in certain contexts by regulating alternative splicing events that influence drug sensitivity. The identification of this regulatory pathway provides potential therapeutic targets for addressing tamoxifen resistance in breast cancer patients. Targeting either SRSF5 directly or its upstream regulators like SRPK1 represents a promising strategy for overcoming treatment resistance .

What strategies should be employed to validate SRSF5 antibody specificity?

Rigorous validation of SRSF5 antibodies is essential for generating reliable research data. A comprehensive validation approach should include multiple complementary techniques:

• Western blot validation:

  • Positive controls: Utilize cell lines known to express SRSF5 (most human cell lines express detectable levels)

  • Negative controls: Ideally include SRSF5 knockout or knockdown samples

  • Expected molecular weight verification: Confirm single band at approximately 31.3 kDa

  • Loading controls: Include housekeeping proteins (β-actin, GAPDH) to normalize expression

• Genetic manipulation controls:

  • siRNA/shRNA knockdown: Demonstrate reduced signal intensity following SRSF5 depletion

  • Overexpression: Show increased signal when SRSF5 is overexpressed with expression constructs

  • CRISPR/Cas9 knockout: Complete loss of signal in knockout cells would provide definitive validation

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide or recombinant SRSF5 protein

  • Observe significant reduction in signal intensity if antibody is specific

  • Include gradient of competing peptide concentrations to demonstrate dose-dependent inhibition

• Cross-validation with multiple antibodies:

  • Compare results using antibodies that target different SRSF5 epitopes

  • Consistent patterns across different antibodies increase confidence in specificity

  • Include both monoclonal and polyclonal antibodies in validation

• Application-specific controls:

  • For immunofluorescence: Include secondary-only controls and pre-immune serum controls

  • For immunoprecipitation: Compare with isotype control antibodies

  • For RIP experiments: Include non-target RNA controls (as demonstrated in the IAV studies with β-actin)

These validation steps should be performed for each application and experimental system. Documentation of validation results increases reproducibility and supports the reliability of research findings involving SRSF5.

What are the optimal experimental conditions for detecting SRSF5 using different techniques?

Successful detection of SRSF5 requires technique-specific optimization. The following protocols outline optimal conditions for various applications:

• Western Blotting (WB):

  • Sample preparation: RIPA or NP-40 buffer with protease inhibitors (consider phosphatase inhibitors for preserving phosphorylation status)

  • Protein loading: 20-50 μg total protein per lane

  • Gel selection: 10-12% SDS-PAGE (appropriate for 31.3 kDa protein)

  • Transfer: PVDF membrane (0.45 μm pore size) with wet transfer

  • Blocking: 5% non-fat milk or BSA in TBST (1 hour, room temperature)

  • Primary antibody: Dilution as per manufacturer's recommendation (typically 1:500-1:2000), overnight at 4°C

  • Detection system: HRP-conjugated secondary antibody with ECL substrate

  • Expected result: Single band at approximately 31.3 kDa (multiple bands may indicate splice variants or post-translational modifications)

• Immunofluorescence (IF)/Immunocytochemistry (ICC):

  • Fixation: 4% paraformaldehyde (15 minutes, room temperature)

  • Permeabilization: 0.2% Triton X-100 in PBS (10 minutes)

  • Blocking: 3% BSA or 10% normal serum in PBS (1 hour)

  • Primary antibody: Manufacturer's recommended dilution (typically 1:50-1:200), overnight at 4°C

  • Nuclear counterstain: DAPI (1 μg/mL, 5 minutes)

  • Expected pattern: Nuclear localization with possible speckled appearance

  • Controls: Include secondary-only control and SRSF5 knockdown cells

• RNA Immunoprecipitation (RIP):

  • Crosslinking: 1% formaldehyde (10 minutes), as used in successful SRSF5-M mRNA interaction studies

  • Lysis buffer: NP-40 buffer with RNase inhibitors

  • Antibody amount: 2-5 μg SRSF5 antibody per sample

  • IP incubation: Overnight at 4°C with rotation

  • Washes: Stringent washing (at least 4 times) to reduce background

  • RNA recovery: TRIzol extraction following crosslink reversal

  • Validation method: RT-qPCR for suspected target RNAs

  • Controls: IgG immunoprecipitation and input samples for normalization

• Co-immunoprecipitation for protein interactions:

  • Lysis conditions: Mild lysis buffer (150 mM NaCl, 1% NP-40 or CHAPS)

  • Pre-clearing: Protein A/G beads (1 hour, 4°C)

  • Antibody binding: 2-5 μg antibody, overnight at 4°C

  • Detection: Western blot for interacting partners (e.g., U1A as identified in viral studies)

These protocols have been successfully employed for SRSF5 detection in various research contexts, including the studies examining SRSF5's role in influenza virus infection and cancer progression .

How does phosphorylation affect SRSF5 function and antibody detection?

Phosphorylation is a critical post-translational modification that regulates SRSF5 activity and can significantly impact antibody-based detection. Research has identified key aspects of SRSF5 phosphorylation:

SRPK1 (serine-arginine protein kinase 1) has been identified as a kinase that interacts with and phosphorylates SRSF5 . This phosphorylation regulates SRSF5's splicing activity, particularly in the context of alternative splicing patterns that influence tamoxifen resistance in breast cancer . Specifically, inhibition of SRPK1 by the small molecule SRPKIN-1 suppresses SRSF5 phosphorylation, altering its activity .

This phosphorylation has important implications for experimental design and antibody-based detection:

• Phosphorylation-state specific detection:

  • Some antibodies may preferentially recognize phosphorylated or non-phosphorylated forms of SRSF5

  • Phospho-specific antibodies can be valuable for studying SRSF5 activation states

  • Total SRSF5 antibodies should ideally detect the protein regardless of phosphorylation status

• Sample preparation considerations:

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers to preserve phosphorylation

  • For dephosphorylation studies, lambda phosphatase treatment can be used as a control

  • Phosphorylation may affect protein extraction efficiency from nuclear compartments

• Electrophoretic mobility:

  • Phosphorylation can cause mobility shifts in SDS-PAGE

  • Multiple bands may represent different phosphorylation states rather than non-specific binding

  • Compare migration patterns before and after phosphatase treatment

• Functional implications:

  • Phosphorylation affects SRSF5's subcellular localization (phosphorylated SR proteins typically accumulate in nuclear speckles)

  • The phosphorylation status influences RNA-binding capacity and splicing activity

  • Consider the potential impact of experimental conditions on phosphorylation state (cell synchronization, stress, drug treatments)

Understanding the phosphorylation dynamics of SRSF5 is crucial for correctly interpreting experimental results, particularly in studies examining its role in disease processes like cancer progression and therapeutic resistance where phosphorylation-dependent activity regulation may be altered .

What methodology should be used for studying SRSF5-RNA interactions?

Investigating SRSF5-RNA interactions requires specialized techniques that preserve the integrity of RNA-protein complexes. Several complementary approaches have proven effective:

• RNA Immunoprecipitation (RIP):

  This technique has been successfully employed to study SRSF5's interactions with viral RNAs, demonstrating a 10-fold enrichment of M mRNA relative to control β-actin mRNA .

  Optimized protocol:

  • Crosslink cells with 1% formaldehyde for 10 minutes

  • Lyse cells in buffer containing RNase inhibitors

  • Immunoprecipitate with 2-5 μg SRSF5 antibody

  • Reverse crosslinks and isolate RNA

  • Analyze by RT-qPCR for specific target RNAs

  • Include appropriate controls: IgG IP, input normalization

• Biotinylated RNA Pull-down:

  This technique was used effectively to demonstrate direct binding between SRSF5 and M mRNA .

  Protocol outline:

  • Generate biotinylated RNA transcripts in vitro

  • Incubate with cell lysates expressing SRSF5 (native or tagged)

  • Capture RNA-protein complexes with streptavidin beads

  • Analyze bound proteins by Western blotting

  • Controls: non-biotinylated RNA, irrelevant RNA sequence

• RNA-Protein Colocalization:

  RNA fluorescence in situ hybridization (FISH) combined with immunofluorescence demonstrated increasing nuclear colocalization of SRSF5 with viral M mRNA during infection .

  Key considerations:

  • Use fluorescently labeled RNA probes for target transcripts

  • Perform immunofluorescence for SRSF5

  • Analyze colocalization using confocal microscopy

  • Quantify colocalization using appropriate software tools

• Binding Site Mapping:

  SRSF5 binding sites on M mRNA were identified at positions 163, 709, and 712 .

  Approaches include:

  • Mutational analysis of predicted binding sites

  • CLIP-seq (Cross-linking immunoprecipitation followed by sequencing)

  • In vitro binding assays with truncated RNA fragments

• Domain Mapping of SRSF5:

  Studies using truncated SRSF5 constructs identified the RRM2 domain as critical for M mRNA binding .

  Methodology:

  • Generate domain deletion or truncation constructs

  • Express in appropriate cell system

  • Perform binding assays with target RNA

  • Compare binding efficiency between constructs

• Quantitative Binding Assessment:

  Microscale thermophoresis technology (MST) was used to demonstrate high affinity binding of full-length SRSF5 and its RRM2 domain to M mRNA .

  Additional approaches:

  • Surface plasmon resonance (SPR)

  • Isothermal titration calorimetry (ITC)

  • Fluorescence anisotropy

These methodologies provide a comprehensive toolkit for investigating SRSF5-RNA interactions at multiple levels, from identifying binding partners to characterizing binding sites and measuring interaction affinities.

How can SRSF5 be targeted for therapeutic interventions in disease states?

SRSF5 represents a promising therapeutic target in several disease contexts, with emerging strategies for intervention:

• In Influenza A Virus (IAV) Infection:

  SRSF5 functions as a pro-viral factor by facilitating M mRNA splicing and viral replication . Targeting approaches include:

  a) Small molecule inhibitors:

  • Anidulafungin, an FDA-approved antifungal drug, was identified as an SRSF5 inhibitor that targets its RRM2 domain

  • This compound effectively blocked IAV replication both in vitro and in vivo

  • Drug repurposing advantage: established safety profile and pharmacokinetics

  b) Genetic approaches:

  • SRSF5 conditional knockout in mouse lung protected against lethal IAV challenge

  • Suggests potential for RNA interference strategies (siRNAs, antisense oligonucleotides)

  • Delivery to respiratory epithelium presents a practical challenge

• In Tamoxifen-Resistant Breast Cancer:

  Low SRSF5 expression correlates with tamoxifen resistance through altered splicing of NCOR2 . Therapeutic strategies include:

  a) Targeting the SRPK1-SRSF5 axis:

  • SRPK1 inhibition by SRPKIN-1 alters SRSF5 phosphorylation and activity

  • This approach could potentially reverse tamoxifen resistance by modifying splicing patterns

  b) Splice-switching oligonucleotides:

  • Direct targeting of NCOR2 pre-mRNA to prevent exon 11 skipping

  • Bypass the need for SRSF5 modulation

  c) Combinatorial approaches:

  • Co-administration of SRPK1 inhibitors with tamoxifen

  • Stratifying patients based on SRSF5 expression levels

• Delivery Strategies and Considerations:

  a) For respiratory infections:

  • Inhaled formulations for direct delivery to lung epithelium

  • Nanoparticle encapsulation to enhance stability and cellular uptake

  b) For cancer applications:

  • Tumor-targeting nanoparticles

  • Antibody-drug conjugates for specific delivery

  c) General considerations:

  • Tissue-specific targeting to minimize off-target effects

  • Dosing regimens that modulate rather than completely inhibit SRSF5 function

  • Patient stratification based on SRSF5 expression or activity biomarkers

The discovery of anidulafungin as an SRSF5 inhibitor with antiviral properties represents a significant advance in developing SRSF5-targeted therapeutics . This finding demonstrates the potential for drug repurposing approaches and provides a foundation for further development of SRSF5-modulating compounds for various disease applications.

What genetic models are available for studying SRSF5 function?

Several genetic modification approaches have been developed to investigate SRSF5 function in different experimental systems:

• Cell Line Models:

  a) RNA interference (RNAi) approaches:

  • siRNA-mediated knockdown in A549 cells significantly reduced viral protein expression during influenza infection

  • Provides temporary reduction in SRSF5 levels suitable for short-term experiments

  • Advantage of simplicity and rapid implementation

  b) CRISPR/Cas9 gene editing:

  • SRSF5 knockout HEK293 cells (srsf5−/−) have been generated and used to study influenza virus replication

  • Provides complete gene elimination for studying loss-of-function effects

  • Potential for introducing specific mutations or tagged versions of SRSF5

• Mouse Models:

  a) Conditional knockout system:

  • Lung-specific SRSF5 conditional knockout mice demonstrated protection against lethal influenza challenge

  • Suggests use of Cre-loxP recombination system with lung-specific promoter

  • Allows for tissue-specific investigation of SRSF5 function while avoiding potential developmental effects

  b) Implications of conditional approach:

  • Complete germline knockout may be embryonically lethal (though not explicitly stated in search results)

  • Tissue-specific deletion allows assessment of adult phenotypes

• Overexpression Systems:

  a) Transient overexpression:

  • SRSF5-Flag expression plasmid transfection in A549 cells significantly increased viral titers during infection

  • Useful for gain-of-function studies

  b) Domain-specific constructs:

  • FLAG-tagged truncated SRSF5 constructs were generated to map functional domains

  • RRM2-GFP fusion construct showed strong colocalization with viral M mRNA

  • Valuable for structure-function relationship studies

• Validation Approaches:

  a) Protein level confirmation:

  • Western blotting with anti-SRSF5 antibodies

  • Detection of tagged versions with anti-tag antibodies

  b) Functional validation:

  • Analysis of alternative splicing patterns of known SRSF5 targets

  • Assessment of cellular phenotypes relevant to SRSF5 function

  c) Controls:

  • Non-targeting siRNA/shRNA for RNAi studies

  • Empty vector transfection for overexpression studies

  • Wild-type littermates for transgenic models

These diverse genetic models provide complementary approaches for investigating SRSF5 function at multiple levels, from molecular mechanisms to physiological relevance in disease contexts such as viral infection and cancer progression.

How do researchers troubleshoot non-specific signals when using SRSF5 antibodies?

Non-specific signals are a common challenge when working with antibodies. For SRSF5 antibodies, consider these troubleshooting strategies:

• Western Blot Issues:

  a) Multiple unexpected bands:

  • Check for known splice variants (search results mention 4 isoforms of SRSF5 produced by alternative splicing)

  • Assess for post-translational modifications, particularly phosphorylation (known to be regulated by SRPK1)

  • Optimize blocking conditions (try 5% BSA instead of milk, which contains phosphatases)

  • Increase washing stringency (higher salt concentration or more detergent)

  • Try alternative antibodies targeting different epitopes

  b) High background:

  • Increase blocking time or concentration

  • Dilute primary antibody further

  • Reduce secondary antibody concentration

  • Use highly cross-adsorbed secondary antibodies

  • Shorten exposure time during imaging

• Immunofluorescence/Immunohistochemistry Issues:

  a) Diffuse staining instead of expected nuclear pattern:

  • Optimize fixation conditions (duration, temperature)

  • Ensure adequate permeabilization for nuclear access

  • Verify antibody penetration with titration experiments

  • Include proper positive controls (cell lines with known SRSF5 expression)

  b) Non-specific cytoplasmic staining:

  • Increase blocking time and stringency

  • Include protein A/G pre-adsorption step

  • Use monoclonal antibodies for higher specificity

  • Include SRSF5 knockdown controls to identify specific signal

• Immunoprecipitation Challenges:

  a) Co-precipitation of non-specific proteins:

  • Pre-clear lysates thoroughly with protein A/G beads

  • Include stringent wash steps (increase salt concentration)

  • Use crosslinking to stabilize antibody-bead interaction

  • Compare results with isotype control antibody

  b) Inefficient target precipitation:

  • Optimize lysis conditions for nuclear proteins

  • Increase antibody amount (2-5 μg recommended)

  • Extend incubation time (overnight at 4°C)

  • Consider epitope availability in native conditions

• RNA Immunoprecipitation Considerations:

  a) Poor RNA recovery:

  • Include RNase inhibitors in all buffers

  • Optimize crosslinking conditions (1% formaldehyde for 10 minutes worked well in published studies)

  • Verify RNase-free working conditions

  • Include input RNA controls and normalize appropriately

  b) Non-specific RNA binding:

  • Include stringent wash steps

  • Compare enrichment to non-target RNAs (β-actin served as an effective control)

  • Use SRSF5 knockdown as negative control

These troubleshooting approaches should help researchers optimize their experimental conditions and distinguish specific SRSF5 signals from background or non-specific interactions.

What is the relationship between SRSF5 and other splicing factors in regulatory networks?

SRSF5 functions within complex regulatory networks involving multiple splicing factors and signaling pathways. Understanding these interactions is crucial for comprehensive analysis of splicing regulation:

• SR Protein Family Interactions:

  SRSF5 belongs to the serine/arginine-rich (SR) protein family, which includes other members like SRSF1, SRSF2, and SRSF3. While the search results don't specifically address interactions between SRSF5 and other SR proteins, these factors often exhibit:

  • Cooperative or antagonistic relationships in regulating specific splicing events

  • Potential functional redundancy, where depletion of one factor may be compensated by others

  • Differential regulation by kinases, allowing for coordinated or independent control

  • Distinct but overlapping RNA binding specificities and target repertoires

• Spliceosome Component Interactions:

  The search results highlight SRSF5's interaction with U1 snRNP during influenza virus infection:

  • SRSF5 recruits U1 snRNP to the viral M pre-mRNA through interaction with the U1A protein

  • This facilitates spliceosome assembly at specific splice sites

  • Such interactions are likely to occur with cellular pre-mRNAs as well, though specific examples are not detailed in the search results

• Regulatory Kinases:

  SR proteins are extensively regulated by phosphorylation. For SRSF5 specifically:

  • SRPK1 (serine-arginine protein kinase 1) has been identified as a kinase that interacts with and phosphorylates SRSF5

  • This phosphorylation affects SRSF5's splicing activity and can be modulated by SRPK1 inhibitors like SRPKIN-1

  • The phosphorylation state likely influences SRSF5's subcellular localization, RNA binding capacity, and protein-protein interactions

• Pathophysiological Context-Dependent Interactions:

  a) In viral infection:

  • SRSF5 expression is induced approximately 3-fold during influenza virus infection

  • It specifically recognizes viral M mRNA through its RRM2 domain

  • This targeted regulation suggests potential competition with other splicing factors for binding sites or spliceosomal components

  b) In cancer progression:

  • SRSF5 regulates alternative splicing of NCOR2, affecting tamoxifen resistance in breast cancer

  • Its reduced expression correlates with production of the BQ variant through exon 11 skipping

  • This suggests potential antagonistic relationships with other splicing factors that might promote exon skipping

Understanding these regulatory networks is essential for predicting the consequences of SRSF5 modulation in both normal physiology and disease states. Further research into SRSF5's interactions with other splicing factors would help elucidate the complex splicing regulatory landscape and identify additional therapeutic opportunities.